Results 291 to 300 of about 67,891 (311)

Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial

Lancet Respiratory Medicine,the, 2021
Neil Barnes, Louis-Philippe Boulet, Nicola A Hanania   +2 more
exaly  

Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study

Lancet Respiratory Medicine,the, 2020
Huib A M Kerstjens, Kenneth R Chapman, Richard N Van Zyl-Smit   +2 more
exaly  

Physical stability of dry powder inhaler formulations

Expert Opinion on Drug Delivery, 2020
Nivedita Shetty, David C Cipolla, Heejun Park   +2 more
exaly  

Effects of switching from a metered dose inhaler to a dry powder inhaler on climate emissions and asthma control: post-hoc analysis

Thorax, 2022
Ashley Woodcock, Christer Janson, David A Leather   +2 more
exaly  

Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial

Lancet, The, 2016
Dave Singh, Alberto A Papi, Massimo Corradi   +2 more
exaly  

Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials

Lancet, The, 2019
Piotr Kuna, Pierluigi Paggiaro, Alberto A Papi   +2 more
exaly  

Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD

New England Journal of Medicine, 2018
David A Lipson, Gerard J Criner, David M G Halpin   +2 more
exaly  

Evaluation of inhaler technique among patients with asthma and COPD in Yemen

Journal of Taibah University Medical Sciences, 2018
Yaser Mohammed Al-Worafi
exaly  

Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes

Journal of Allergy and Clinical Immunology: in Practice, 2017
David B Price, R Brett Mcqueen, Sinthia Bosnic-Anticevich BPharm   +2 more
exaly